Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.47 |
| ▸ | SKP1 | P63208 | 2/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | GALR2 | O43603 | 1/20 | 0.42 |
| ▸ | GALR1 | P47211 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296437 | 1.00 | CKS1B (0.47) | CKS1BSKP1SKP2GPR119KMT2A | |
| SCHEMBL4290422 | 0.87 | PRKCQ (0.44) | KMT2AHRH3USP2MAPK1SMN1; SMN2 | |
| SCHEMBL4290403 | 0.87 | PRKCQ (0.44) | KMT2AHRH3USP2MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4304161 | 0.86 | PRKCQ (0.43) | KMT2AHRH3USP2MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4304166 | 0.86 | PRKCQ (0.43) | KMT2AHRH3USP2MAPK1SMN1; SMN2 | |
| SCHEMBL3467261 | 0.83 | CKS1B (0.52) | CKS1BSKP1SKP2GPR119KMT2A | |
| SCHEMBL3467257 | 0.83 | CKS1B (0.52) | CKS1BSKP1SKP2GPR119KMT2A | |
| SCHEMBL4294947 | 0.81 | PRKCA (0.44) | KMT2AHRH3USP2MAPK1SMN1; SMN2 | |
| SCHEMBL4297766 | 0.81 | PRKCA (0.44) | KMT2AHRH3USP2MAPK1SMN1; SMN2 | |
| SCHEMBL4293266 | 0.81 | PRKCA (0.44) | KMT2AHRH3USP2MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | HTR6, HTR5A, TPH1 | CKS1B 2221/4885SKP1 1913/4885SKP2 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.